Atenção!


O atendimento às questões referentes ao Repositório Institucional será interrompido entre os dias 20 de dezembro de 2024 a 5 de janeiro de 2025.

Pedimos a sua compreensão e aproveitamos para desejar boas festas!

 

Encapsulating Anti-Parasite Benzimidazole Drugs into Lipid-Coated Calcium Phosphate Nanoparticles to Efficiently Induce Skin Cancer Cell Apoptosis

dc.contributor.authorMovahedi, Fatemeh
dc.contributor.authorGu, Wenyi
dc.contributor.authorSoares, Christiane Pienna [UNESP]
dc.contributor.authorXu, Zhi Ping
dc.contributor.institutionThe University of Queensland
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.date.accessioned2022-04-29T08:39:58Z
dc.date.available2022-04-29T08:39:58Z
dc.date.issued2021-06-15
dc.description.abstractBenzimidazole (BMZ) family of anti-worm drugs has been now repurposed as anti-cancer drugs. However, offering a general reformulation method for these drugs is essential due to their hydrophobicity and low aqueous solubility. In this work, we developed a general approach to load typical BMZ drugs as tiny nanocrystals within lipid-coated calcium phosphate (LCP) nanoparticles. BMZ drug-loaded LCP nanoparticles increased their solubility in PBS by 100–200% and significantly enhanced the anti-cancer efficacy in the treatment of B16F0 melanoma cells. These drug-LCP nanoparticles induced much more cancer cell apoptosis, generated much more reactive oxygen species (ROS) and inhibited Bcl-2 expression of cancer cells. Moreover, BMZ drug-loaded LCP nanoparticles caused morphological change and extension disruption of cancer cells, and significantly reduced migration activity, representing high possibility for inhibition of tumor dissemination and metastasis. Very advantageously, BMZ drug-loaded LCP nanoparticles did not show any obvious toxicity, Bcl-2 inhibition and morphological changes in HEK293T healthy cells. In conclusion, BMZ drug-incorporated LCP nanoformulations may be a valuable nanomedicine that is able to inhibit primary tumors and prevent tumor dissemination with minimum side effects on healthy cells and tissues.en
dc.description.affiliationAustralian Institute for Bioengineering and Nanotechnology (AIBN) The University of Queensland
dc.description.affiliationDepartment of Clinical Analysis School of Pharmaceutical Sciences Universidade Estadual Paulista (UNESP)
dc.description.affiliationUnespDepartment of Clinical Analysis School of Pharmaceutical Sciences Universidade Estadual Paulista (UNESP)
dc.identifierhttp://dx.doi.org/10.3389/fnano.2021.693837
dc.identifier.citationFrontiers in Nanotechnology, v. 3.
dc.identifier.doi10.3389/fnano.2021.693837
dc.identifier.issn2673-3013
dc.identifier.scopus2-s2.0-85125145588
dc.identifier.urihttp://hdl.handle.net/11449/230445
dc.language.isoeng
dc.relation.ispartofFrontiers in Nanotechnology
dc.sourceScopus
dc.subjectbenzimidazole family of anti-worm drugs
dc.subjectenhanced anti-cancer toxicity
dc.subjectenhanced solubility
dc.subjectinhibition of cancer dissemination
dc.subjectlipid-coated calcium phosphate nanoparticles
dc.titleEncapsulating Anti-Parasite Benzimidazole Drugs into Lipid-Coated Calcium Phosphate Nanoparticles to Efficiently Induce Skin Cancer Cell Apoptosisen
dc.typeArtigo
unesp.departmentAnálises Clínicas - FCFpt

Arquivos